Evidence map›Paper›PMID 39313898›Full record

ArticleCurrent pharmaceutical biotechnology2025

The Effect of Erythromycin in Macrolide-resistant

Kaichong Jiang, Yang Luan, Wei Wang, Da Xue, Shuyue Tang, Xiaokang Peng, Xiaoguai Liu, Zengguo Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kaichong JiangNational Regional Children's Medical Center (Northwest), Shaanxi Institute for Pediatric Diseases, Xi'an Children's Hospital, Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710003, China.
Yang LuanMicrobiology and Biology Laboratory, Xi'an Municipal Center for Disease Control and Prevention, Xi'an, Shaanxi, 710054, China.
Wei WangNational Regional Children's Medical Center (Northwest), Department of Clinical Laboratory, Xi'an Children's Hospital, Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710003, China.
Da XueSchool of Public Health, Shaanxi University of Chinese Medicine, Xi'an, Shaanxi, 712046, China.
Shuyue TangSchool of Public Health, Shaanxi University of Chinese Medicine, Xi'an, Shaanxi, 712046, China.
Xiaokang PengNational Regional Children's Medical Center (Northwest), Department of Infectious Diseases, Xi'an Children's Hospital, Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710003, China.
Xiaoguai LiuNational Regional Children's Medical Center (Northwest), Department of Infectious Diseases, Xi'an Children's Hospital, Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710003, China.
Zengguo WangNational Regional Children's Medical Center (Northwest), Department of Clinical Laboratory, Xi'an Children's Hospital, Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710003, China.

Funding

National Natural Science Foundation of China 8217081223Shaanxi Health and Family Planning Commission 2021E002
6 · The paper itself

Abstract

introductionThe macrolide-resistant Bordetella pertussis (MRBp) has appeared in Asia and has even been prevalent in China. Since the antibiotic sensitivity test is not carried out in the clinical setting, macrolide is still the first choice of antibiotic in MRBp infection. Further, the macrolide therapy for pertussis needs to be revised. Macrolide has always shown a positive effect on other macrolide-resistant bacterium infections in clinical applications. However, the mechanism of macrolide on MRBp remains unclear.

objectiveThe objective of this study was to investigate the effect of virulence of MRBp under the sub-MIC erythromycin.

methodsThis study evaluated a representative isolate BP19147 (

resultsThe proteomics was detected by label-fee DIA. The growth ability and virulence factors of MR isolate BP19147 were inhibited by sub-MIC of erythromycin and had a concentration- dependent effect. From the proteomics results, the pertussis toxin, filamentous haemagglutinin, and pertactin did not show a statistical difference (p >0.05). Other virulence factors (including dermonecrotic toxin, Invasive Adenylate cyclase/haemolysin. etc) showed a statistical difference (p <0.05). In the KEGG enrichment, the BvgAS system, biofilm formation, and some adaptive systems were inhibited by erythromycin.

conclusionThe sub-MIC of erythromycin may reduce the virulence of MRBp, which will provide a theoretical basis for the rational use of erythromycin for MRBp infection and help the development of new antibiotics.

Indexed as

Anti-Bacterial AgentsBordetella pertussisErythromycinBiofilmsDrug Resistance, BacterialHumansMacrolidesMicrobial Sensitivity TestsVirulenceAnti-Bacterial AgentsErythromycinMacrolidesBordetella pertussiserythromycinMRBp infection.proteomicsresistancevirulence factors

Identifiers

PMID39313898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.